News

MEDICAL ALLEY, MINNESOTA, UNITED STATES, September 27, 2021 /EINPresswire.com/ -- SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of sciatica) announced today that Vicki Gashwiler has joined the company as the Vice President of Global Clinical Operations.

MEDICAL ALLEY, MINNESOTA, UNITED STATES, July 26, 2021 /EINPresswire.com/ -- SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of sciatica) announced today that the United States Patent and Trademark Office (USPTO) has recently issued U.S. Patent Number 10,925,883 entitled Pharmaceutical Compositions and Uses Thereof. The issuance of the ‘883 patent will add to the company’s growing worldwide patent portfolio and is already issued in nineteen other countries. The issued claims of this patent family are directed at composition coverage of SpineThera’s novel biodegradable, sustained-release microsphere platform technologies. The company’s lead product, SX600, is currently being evaluated in a Phase 2 clinical trial for lumbar radiculopathy (sciatica) in Australia.

MEDICAL ALLEY, Minnesota. – November 25, 2019 –SpineThera, Inc., and its subsidiary SpineThera Australia Pty Ltd, announced today the first dose has been administered in the SALIENT (Safety and Efficacy of SX600 Administered by Lumbosacral Transforaminal Epidural Injection for Radicular Pain) Phase 1/2 clinical study of SX600, a non-opioid epidural steroid injection in development for the treatment of sciatica.

SpineThera’s clinical development program for SX600 will evaluate sustained-release, injectable treatment options for pain in and near the spine Minneapolis, MN – August 22, 2019 - SpineThera, Inc., a privately held, clinical stage pharmaceutical company, announced today that the United States Patent and Trademark Office has issued Patent 10,350,222 related to its non-opioid, sustained-release drug technology.